Cystic Fibrosis - Pipeline Review, H2 2018

Transcription

1 Cystic Fibrosis - Pipeline Review, H2 2018

2 Cystic Fibrosis - Pipeline Review, H BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or reportstore@bioportfolio.com 2

3 Cystic Fibrosis - Pipeline Review, H Cystic Fibrosis - Pipeline Review, H Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Pipeline Review, H2 2018, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 29, 27, 60 and 30 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively. Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory). - The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. 3

4 - The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Additional Details Publisher : Global Markets Direct Reference : GMDHC10807IDB Number of Pages : 435 Report Format : PDF Publisher Information : 4

5 5

6 Table Of Contents for Cystic Fibrosis - Pipeline Review, H [Report Updated: ] Table of ContentsTable of Contents 2Introduction 6Cystic Fibrosis - Overview 7Cystic Fibrosis - Therapeutics Development 8Cystic Fibrosis - Therapeutics Assessment 29Cystic Fibrosis - Companies Involved in Therapeutics Development 41Cystic Fibrosis - Drug Profiles 76Cystic Fibrosis - Dormant Projects 395Cystic Fibrosis - Discontinued Products 403Cystic Fibrosis - Product Development Milestones 404Appendix 417 6

7 How to Buy... Cystic Fibrosis - Pipeline Review, H [Report Updated: ] Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $2000 Single User Price $4000 Site License Price $6000 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 7